One calm, cited email a week.

One compound, one new trial, or one regulatory update — read and analyzed in roughly the time it takes to finish a coffee.

No upsells, no affiliate placements, no 4,000-word emails. The reader on the other side of this list already knows the Wikipedia entry and the Examine.com stub. We try to add the third thing — the trial we read, the effect size that surprised us, the regulatory detail most coverage missed.

Subscribers also receive The 2026 Peptide Evidence Ledger — a 12-page PDF covering ten major compounds with the same four-tier framework we use on every profile: Preclinical / Human pilot / Phase trial / FDA status. Updated quarterly.